Finasteride Hair Loss Results: What the Trials Show
How effective is finasteride at stopping hair loss and regrowing hair?
The honest way to judge this drug isn't against a photo of someone with a full head of hair, it's against what your own scalp does over the next five years if you leave it alone. On that measure it's one of the better documented things in dermatology, and what it mainly buys you is defence rather than reversal. It cuts scalp DHT by roughly sixty percent, which takes away most of the hormonal pressure that's been shrinking your follicles, and the numbers below are what that translates into.
Oral finasteride at one milligram daily left about eighty-three percent of treated men with no further hair loss by hair count at two years against roughly twenty-eight percent on placebo, and about ninety percent showed no continued visible loss at five years.
How long does treatment take before any change is visible in the mirror?
Scalp DHT falls within days of your first tablet, but the follicles it protects are locked into growth phases that run for years. That mismatch is the whole reason patience isn't a platitude here: a follicle just released from hormonal suppression still has to finish its cycle, shed, and push out a thicker shaft before you can see anything.
- Months 0 to 3: Nothing visible, and a temporary jump in shedding is common as weak hairs cycle out ahead of better ones.
- Month 3: The earliest point men start reporting improvement themselves, and the labelling's stated minimum before any benefit shows.
- Month 6: Measurable hair count change reached significance here under standardized photography.
- Months 12 to 24: The curve peaks, then settles into a long plateau you maintain rather than extend.
Measurable hair count improvement reached statistical significance by six months in the registration trials, with the response peaking between twelve and twenty-four months before plateauing.
Which parts of the scalp respond well and which barely respond at all?
Response is regional, and the map is consistent enough that you can set your expectations zone by zone before you start. What most people get wrong is assuming a tablet works evenly across the scalp; the temples and the crown behave almost like different problems.
Follicle sensitivity to DHT and 5-alpha-reductase expression differ by scalp region, which is why vertex and mid-scalp counts improve most while temporal recession often continues at a slower rate.
What happens to the hair that was saved or regrown if treatment stops?
None of this benefit is banked. The drug suppresses an ongoing signal, it doesn't repair your follicles' genetic susceptibility to that signal, so the clock restarts the moment you stop. The cruel part isn't extra loss, it's compression: the years of loss the treatment held off arrive inside about twelve months.
- Clearance: Mean terminal plasma half-life is about four and a half hours, so DHT rebounds to baseline fast.
- Twelve-month reversal: Men switched to placebo after a year had lost the entire hair count gain within twelve months.
- No rebound penalty: Density converges on your untreated trajectory, it doesn't drop below it.
- Missed doses: A skipped day rarely matters; months off and on trade away the steady suppression the result depends on.
Men withdrawn from treatment after twelve months lost their entire hair count gain within the following twelve months, returning to the density they would have had without treatment, with no rebound below that trajectory.
How do results compare with topical minoxidil, and does combining the two help?
These two aren't rivals, they intervene at different points in the same problem. One removes the cause by cutting the DHT signal, which makes it slow and protective; the other works downstream on the hair cycle itself, which makes it faster but blind to the hormonal pressure underneath. That's exactly why using both beats using either.
| Criteria | Oral finasteride | Topical minoxidil |
|---|---|---|
| Mechanism | Cuts the DHT signal driving miniaturization | Opens potassium channels, lengthens the growth phase |
| Speed of visible change | Slower, months before anything shows | Earlier cosmetic thickening |
| Effect on further loss | The stronger performer | Little effect on the underlying cause |
| Hair count effect | Larger and more durable | Smaller, and behind combination therapy |
| If you stop | Gains gone within about a year | Gains lost over months as well |
Comparative trials put combined finasteride and topical minoxidil ahead of either drug alone, with finasteride alone or in combination significantly outperforming minoxidil alone on hair count.
Why do two men on the same dose get very different results?
The same tablet doesn't mean the same exposure or the same biology, and the variation arrives from at least four directions at once. Before you write yourself off as a non-responder, work through them, because three of the four are fixable and one of them looks identical to biological failure in the mirror.
- Receptor biology: Androgen receptor variants, receptor density and local enzyme expression all differ between scalps.
- Timing: The drug protects follicles that still exist, so fifteen untreated years leaves far less to rescue.
- Adherence: Patchy use across a two-year window looks exactly like the drug not working.
- A second diagnosis: Thyroid disease, low iron, big weight loss or traction shed hair no androgen-directed drug touches.
Finasteride inhibits type II 5-alpha-reductase and barely touches the type I isoform, which contributes more in some individuals than others, so identical dosing produces genuinely different amounts of DHT relief from one scalp to the next.
Does starting earlier in the hair loss process change the ceiling on results?
Yes, and it's the one consequential variable you actually control. Pattern loss shrinks the follicle across successive cycles until it's replaced by connective tissue, and no drug regenerates a follicle that's already gone. So your ceiling is set by what's still on your scalp, not by your age.
A drug that removes the shrinking signal can let a miniaturized follicle recover toward its former calibre, but once perifollicular fibrosis has replaced the follicle with connective tissue no medical treatment restores it.
How is effectiveness actually measured in clinical trials?
Once you know what the instruments actually measure, the gap between the published numbers and what people expect them to mean mostly closes. A result can be strongly significant and still look undramatic, because the primary endpoint describes a coin-sized patch of scalp rather than your whole head.
- Target area hair count: Hairs counted inside a tattooed one-inch circle, clipped short and photographed under fixed conditions.
- Blinded global photographic assessment: A dermatologist panel scores before and after shots on a seven-point scale, allocation and order hidden.
- Questionnaires: Patient and investigator ratings, which often disagree with the counts in both directions.
The primary objective endpoint in these trials is the hair count inside a tattooed one-inch diameter circle on the scalp, so a statistically significant ten percent gain in that zone is real but describes a coin-sized area rather than the whole head.
How effective is it for women with pattern hair loss?
This is a different clinical question, not the male answer handed to a different patient, and it opens with a hard safety boundary rather than an efficacy figure. Because DHT drives normal development of male external genitalia, exposure in pregnancy carries a recognized risk of harm to a male fetus. The effectiveness evidence behind it is also far weaker than anything quoted for men.
Finasteride is contraindicated in women who are or may become pregnant because of the recognized risk of harm to a male fetus, and it is not approved for female pattern hair loss in most jurisdictions, where topical minoxidil remains the only approved option.
Does a higher dose or a topical formulation produce better results?
More isn't better here, and that's a measured flat curve rather than caution talking. Dose-ranging work found scalp DHT suppression and hair count response level off at or near one milligram daily, so raising the dose isn't the answer to a weak result. The formulation question is the genuinely interesting one, since most of the worry about this drug is about systemic androgen effects rather than local ones.
| Criteria | One milligram oral daily | Low-concentration topical |
|---|---|---|
| Hair count response | The benchmark; plateaus at or near 1 mg | Comparable in a phase three trial |
| Serum DHT suppression | Full systemic suppression | Markedly less, though not zero |
| Longer-term evidence | Two-year and five-year controlled data | Thinner, shorter follow-up |
| Product consistency | Fixed tablet strength | Varies by compounding pharmacy and vehicle |
Scalp DHT suppression and hair count response plateau at or near one milligram daily, with five milligrams delivering no additional hair benefit while producing more systemic effect and doses as low as two tenths of a milligram delivering much of the same response.
